JAMES CHRISTENSEN: Open Payments
NPI 1447238688 · COFFEYVILLE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 32 payments from 12 companies in 2025. Trend: 2023 $502 · 2024 $360 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $141 |
| Supernus Pharmaceuticals, Inc. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| PFIZER INC. | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Novo Nordisk Inc | 2 | $51 |
| Boston Scientific Corporation | 2 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $43 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| ABBVIE INC. | 3 | $41 |
Products named: Qelbree, CAPLYTA, PREVNAR 20, BREZTRI, REXULTI, WATCHMAN Access System, FARXIGA, Kerendia.
Industry payments across KS — which companies pay providers there.
